Yes, he owns 20M+ shares purchased at high $34. He is an insider with one board seat, so if he washes his hands he his to do insider filing.
Bystolic only has one weak patent (challenged by 7 co-first-to-file). Generic Bystolic may come in this December or mid 2014. Whenever it comes, Bystolic's value will dissolve like ice under summer sun with 7 challengers launching generics at the same time.
Counting on Bystolic Cliff and Namenda Cliff, FRX's PPS may never see $30 before 2020.